Peer-reviewedCC BYFrontiers in public health
Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs
7 affiliations
- 1CURE Drug Repurposing Collaboratory, Critical Path Institute , , ,
- 2Myalgic Encephalomyelitis Action Network , , ,
- 3Patient Led Research Collaborative , , ,
- 4Global Cures, Inc. , , ,
- 5Emory University School of Medicine , , ,
- 6Retired M.D. , , ,
- 7Stanford University School of Medicine , , ,
Abstract
Long COVID is an emerging chronic condition that results in substantial impairments in quality of life, physical function, and ability to maintain gainful employment. There are no FDA-approved treatments for Long COVID, and recent institution-based clinical trials have not yielded effective treatments. Current standard of care involves trial-and-error drug repurposing that warrants evaluation in rigorous clinical trials. Here we describe potential advantages of decentralized repurposing drug trials as an alternative or complementary approach to institution-based trials. Additionally, we describe lessons learned when launching a local feasibility pilot trial that may inform the design of future decentralized trials in the Long COVID field.
Related
- Barriers and Facilitators Influencing Physiotherapists’ Adherence to Clinical Practice Guidelines and Return to Sport Criteria after Anterior Cruciate Ligament Reconstruction: A Qualitative Study in Austria.
- Uptake, Barriers, and Facilitators of Open Science in Clinical Psychology: Findings from an Exploratory Survey in German-speaking Countries
- Early mobility to improVE health outcomes following cardiac surgery (EVE) clinical trial development: findings from workshop 2-co-created definition and prioritized barriers, facilitators and outcome and experience measures.
- Barriers and facilitators to translating infection prevention knowledge into clinical practice at Bule Hora University Teaching Hospital, Ethiopia: mixed-methods study
- Healthcare providers perceptions of barriers and facilitators to implementation of an acute traumatic brain injury clinical practice guideline: a CFIR-informed qualitative study at a regional referral hospital in Northern Tanzania
BibTeX
@article{schito2026facilitators,
title = {{Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs}},
author = {Marco Schito and Stacey Coe and Jaime Seltzer and Hannah E. Davis and Vidula Sukhatme and Theodore W. Johnson II and Judy Stone and Alexander D. Truong and Linda N. Geng and Tiffany A. Walker},
journal = {Frontiers in public health},
year = {2026},
month = sep,
doi = {10.3389/fpubh.2026.1822376},
url = {https://europepmc.org/article/PMC/PMC13661906},
note = {CC BY},
}
RIS
TY - JOUR
TI - Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs
AU - Marco Schito
AU - Stacey Coe
AU - Jaime Seltzer
AU - Hannah E. Davis
AU - Vidula Sukhatme
AU - Theodore W. Johnson II
AU - Judy Stone
AU - Alexander D. Truong
AU - Linda N. Geng
AU - Tiffany A. Walker
PY - 2026
DA - 2026/09/30
JO - Frontiers in public health
DO - 10.3389/fpubh.2026.1822376
UR - https://europepmc.org/article/PMC/PMC13661906
AB - Long COVID is an emerging chronic condition that results in substantial impairments in quality of life, physical function, and ability to maintain gainful employment. There are no FDA-approved treatments for Long COVID, and recent institution-based clinical trials have not yielded effective treatments. Current standard of care involves trial-and-error drug repurposing that warrants evaluation in rigorous clinical trials. Here we describe potential advantages of decentralized repurposing drug trials as an alternative or complementary approach to institution-based trials. Additionally, we describe lessons learned when launching a local feasibility pilot trial that may inform the design of future decentralized trials in the Long COVID field.
SN - 2296-2565
ER -